Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBT 176

Next Previous
Search
Drug Profile

BBT 176

Alternative Names: BBT-176

Latest Information Update: 15 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Research Institute of Chemical Technology
  • Developer Bridge Biotherapeutics
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 29 Nov 2023 Bridge Biotherapeutics terminates phase I/II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea considering the changing treatment landscape for NSCLC (PO) (NCT04820023)
  • 09 Sep 2023 Adverse events data from a phase I/II trial in Non-small cell lung cacner presented at the 24th World Conference on Lung Cancr (WCLC-2023)
  • 09 Aug 2022 Interim efficacy and adverse events data from a phase I/II trial in Non-small cell lung cacner released by Bridge Biotherapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top